IRIS
SIGNORIELLO, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.618
NA - Nord America 2.085
AS - Asia 1.991
SA - Sud America 388
AF - Africa 30
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.117
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.338
US - Stati Uniti d'America 2.024
SG - Singapore 682
CN - Cina 436
IE - Irlanda 406
BR - Brasile 333
HK - Hong Kong 312
VN - Vietnam 273
IT - Italia 266
DE - Germania 164
GB - Regno Unito 163
KR - Corea 104
IN - India 52
UA - Ucraina 47
FR - Francia 42
JP - Giappone 34
GR - Grecia 32
MX - Messico 31
FI - Finlandia 30
AR - Argentina 29
BD - Bangladesh 24
CA - Canada 20
SE - Svezia 20
PL - Polonia 19
TR - Turchia 17
AT - Austria 14
NL - Olanda 14
IQ - Iraq 12
ES - Italia 11
BE - Belgio 10
CZ - Repubblica Ceca 10
ID - Indonesia 10
EC - Ecuador 9
HU - Ungheria 7
PK - Pakistan 7
LT - Lituania 6
MA - Marocco 6
TN - Tunisia 6
CH - Svizzera 5
IL - Israele 5
ZA - Sudafrica 5
CO - Colombia 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
BO - Bolivia 3
CR - Costa Rica 3
EG - Egitto 3
PT - Portogallo 3
PY - Paraguay 3
RS - Serbia 3
AU - Australia 2
BY - Bielorussia 2
CL - Cile 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
JM - Giamaica 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PE - Perù 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GT - Guatemala 1
IR - Iran 1
IS - Islanda 1
KZ - Kazakistan 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.117
Salva come PNG Salva come JPEG
Città #
Moscow 1.165
Dublin 404
Hong Kong 308
Santa Clara 302
San Jose 300
Singapore 288
Chandler 148
Ashburn 110
Seoul 103
Ho Chi Minh City 100
Dallas 95
Hefei 87
Jacksonville 80
Beijing 70
Hanoi 56
Munich 55
Princeton 53
Roxbury 53
New York 52
Bremen 46
Naples 43
Caserta 42
Los Angeles 40
The Dalles 36
Ann Arbor 32
Bengaluru 32
Cambridge 30
Medford 30
São Paulo 30
Redhill 26
Memphis 21
Milan 19
Boardman 18
Da Nang 16
Warsaw 16
Wilmington 16
Aversa 14
Des Moines 14
Nuremberg 13
Rio de Janeiro 13
Haiphong 12
Helsinki 12
Norwalk 12
Brussels 10
Mexico City 10
Turku 10
Falkenstein 9
San Francisco 9
Toronto 9
Atlanta 8
Houston 8
Ninh Bình 8
Orem 8
Phoenix 8
Amsterdam 7
Belo Horizonte 7
Boston 7
Chicago 7
Frankfurt am Main 7
Nanjing 7
Rome 7
Stockholm 7
Tokyo 7
Ankara 6
Denver 6
Miami 6
Redwood City 6
San Mateo 6
Thái Bình 6
Tianjin 6
Vienna 6
Brasília 5
Buffalo 5
Casablanca 5
Chennai 5
Council Bluffs 5
Guarulhos 5
Jinan 5
London 5
Mountain View 5
Quảng Ngãi 5
Salto 5
Seattle 5
Baghdad 4
Brooklyn 4
Can Tho 4
Cercola 4
Curitiba 4
Guangzhou 4
Hyderabad 4
Jakarta 4
Marcianise 4
Montreal 4
Nanchang 4
Phú Nhuận 4
Prague 4
Quito 4
San Giorgio A Cremano 4
Santa Maria 4
São José dos Pinhais 4
Totale 4.748
Salva come PNG Salva come JPEG
Nome #
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 176
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 165
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 162
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 157
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 155
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 155
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 154
Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease 152
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 152
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 152
Is the pathology of posterior cortical atrophy clinically predictable? 151
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 148
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 144
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 143
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 141
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 141
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 140
Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study 138
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 138
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 136
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. 136
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 136
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 135
Clinical activity after fingolimod cessation: disease reactivation or rebound? 135
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families 132
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 129
Disability assessment using Google Maps 129
A real-world study of alemtuzumab in a cohort of Italian patients 129
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 128
Signs and symptoms of COVID-19 in patients with multiple sclerosis 127
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 125
Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition 124
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 123
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 122
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 117
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 117
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 116
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 116
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 116
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 115
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis 114
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 112
Migraine as possible red flag of PFO presence in suspected demyelinating disease 112
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 110
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 106
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 106
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 105
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study 102
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 100
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 99
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity 98
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 98
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 97
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 96
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 96
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series 94
Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood 94
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis 93
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 93
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report 93
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 88
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 88
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 87
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue 85
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) 85
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. 85
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 82
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 81
Integrated cognitive and neuromotor rehabilitation in multiple sclerosis: A pragmatic study 81
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 80
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 76
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study 76
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 75
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis 75
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 72
Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. 71
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 70
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study 70
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab 70
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 65
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 65
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 63
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 62
Theory of mind in multiple sclerosis: Three-month follow-up effects after double-blind tDCS and video-training, a pilot study 30
Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm 18
Totale 9.325
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.795
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022422 13 38 3 12 99 7 10 8 30 50 25 127
2022/2023701 72 18 9 45 79 42 0 35 353 6 23 19
2023/2024376 23 11 22 21 107 41 33 5 8 3 24 78
2024/20251.432 2 22 8 47 210 194 150 125 228 208 136 102
2025/20265.875 193 291 356 281 498 3.095 346 258 193 143 140 81
2026/202718 18 0 0 0 0 0 0 0 0 0 0 0
Totale 9.325